

Nirmatrelvir/Ritonavir (Paxlovid®) 5-day Treatment Pack Prescription

HLTH 2368 2022/05/12 PAGE 2 OF 2

Nirmatrelvir/ritonavir (Paxlovid®) is indicated for use in patients **18 years** and older with **mild/moderate COVID-19 infection** who are **at risk for disease progression**:

- **Individuals** identified as Clinically Extremely Vulnerable Group 1¹, Group 2², and Group 3³ (**CEV 1, CEV 2, and CEV 3**), **regardless of vaccine status** or previous infection. (See Practice Tool 2 – CEV Definitions).
- **Unvaccinated individuals** without previous infection **who are EITHER:**
 - **≥50 years OR**
 - have **three or more chronic conditions/co-morbidities**⁴ (e.g., obesity, diabetes, heart failure, stroke, neurological conditions)
- **Individuals ≥ 50 years with 1-2 vaccine doses** or previous infection alone, with three or more chronic conditions/co-morbidities⁴ (e.g., obesity, diabetes, heart failure, stroke, neurological conditions)
- **Individuals aged ≥70 years with 1-2 vaccine doses** or previous infection alone, **with one or more chronic condition/co-morbidity**⁴ (e.g., obesity, diabetes, heart failure, stroke, neurological conditions)
- **Individuals ≥ 70 years with three or more chronic conditions/co-morbidities**⁴ (e.g., obesity, diabetes, heart failure, stroke, neurological conditions), regardless of vaccine status or previous infection
- **Indigenous individuals** (if not captured above) **who are EITHER:**
 - **unvaccinated** without previous infection OR
 - **≥ 50 years with 1-2 vaccine doses** or with previous infection alone OR
 - **≥ 70 years regardless of vaccine status** or previous infection

¹. CEV Group 1 includes severe immunocompromise e.g., solid organ transplant, stem-cell transplant or CAR-T cell therapy, active treatment for hematological malignancies, B-cell depleting and anti-CD 40 therapy

². CEV Group 2 includes moderate immunocompromise e.g., solid tumor cancer treatment, active hematological malignancy, immunosuppressive therapy, primary immunodeficiencies and advanced/untreated HIV

³. CEV Group 3 includes high-risk conditions e.g., cystic fibrosis, severe asthma or severe COPD, diabetes requiring insulin, developmental or intellectual disabilities, rare metabolic or blood disorders and others

⁴. Many additional chronic conditions can be considered. Consult Practice Tool #1 – Step by Step Assessment

To be eligible, patient has none of the exclusion criteria listed below:

- History of significant liver disease – cirrhosis, active hepatitis (ALT 5x ULN), or severe liver dysfunction (Child-Pugh C)
- Moderate-severe renal impairment requiring renal replacement therapy or known eGFR less than 30 mL/min
- History of hypersensitivity or other contraindication to any of the components of medication

*Covid Clinical Practice Tools:

<http://www.bccdc.ca/health-professionals/clinical-resources/covid-19-care/clinical-care/treatments>

As of March 1, 2022, prescriptions can be faxed to community pharmacies. For list of pharmacies that dispense Paxlovid, please see <https://www.bcpharmacy.ca/paxlovid>